A Form 4 filed on October 29, 2026 reports that Kevin Tang, a director and 10% owner of Boundless Bio, Inc. (NASDAQ:BOLD), acquired 10,707 shares of common stock on October 27, 2026 at a weighted-average price of $2.40 per share.

Key Highlights

  • Transaction date: October 27, 2026, with the filing submitted on October 29, 2026.
  • Shares acquired: 10,707 shares of Boundless Bio, Inc. common stock, coded as a purchase (P).
  • Weighted-average price: $2.40 per share, with individual transactions ranging from $2.38 to $2.40, according to the filing.
  • Beneficial ownership following the transaction: 3,022,456 shares held indirectly.
  • Indirect ownership structure: Shares are held across Tang Capital Partners, LP (691,177 shares), Tang Capital Partners International, LP (961,511 shares), Tang Capital Partners III, Inc. (691,170 shares), and Tang Capital Partners IV, Inc. (678,598 shares), as disclosed in the filing.
  • Reporting persons: Kevin Tang and Tang Capital Management LLC, both listed at the same San Diego, California address.

Tang Capital Entities Add to Boundless Bio Position in October 2026

According to the Form 4 filing, Kevin Tang purchased 10,707 shares of Boundless Bio, Inc. common stock on October 27, 2026. The filing identifies Tang as both a director and a 10% owner of the issuer. The reported price of $2.40 represents a weighted average, with the filing noting that individual transactions occurred at prices ranging from $2.38 to $2.40 per share. The filing states that the reporting persons will provide details on the number of shares purchased at each price within that range upon request by the issuer, any security holder, or SEC staff.

The acquired shares are held indirectly through a network of affiliated entities. As disclosed in the filing, Tang Capital Partners, LP holds 691,177 shares; Tang Capital Partners International, LP holds 961,511 shares; Tang Capital Partners III, Inc. holds 691,170 shares; and Tang Capital Partners IV, Inc. holds 678,598 shares. The filing explains that Kevin Tang is the sole manager of Tang Capital Management, LLC, which serves as the general partner of Tang Capital Partners, LP and Tang Capital Partners International, LP. Kevin Tang is also described as the sole director and Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc., both of which are indirectly wholly owned by Tang Capital Partners, LP. The filing states that Tang has a pecuniary interest in the shares held by all four entities.

Following the reported transaction, the total indirectly beneficially owned shares stand at 3,022,456, as stated in Table I of the filing. No derivative securities transactions were reported.

What Was Disclosed

The filing discloses a purchase of 10,707 shares of Boundless Bio, Inc. common stock by Kevin Tang on October 27, 2026, at a weighted-average price of $2.40, bringing his indirect beneficial ownership to 3,022,456 shares held across four Tang Capital entities.